Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Meteb Al‑Foheidi"'
Publikováno v:
Case Reports in Oncological Medicine, Vol 2019 (2019)
Introduction. Granulocyte colony-stimulating factor (G-CSF) is commonly used for prevention and treatment of febrile neutropenia among solid tumor patients. It is considered an effective and relatively safe supportive care medication; however, it can
Externí odkaz:
https://doaj.org/article/0cd5bbd059384caf85e1d27c6c11687a
Autor:
Consuela Cheriece Yousef, Mansoor Ahmed Khan, Hind Almodaimegh, Majed Alshamrani, Meteb Al-Foheidi, Hana AlAbdalkarim, Ahmed AlJedai, Anjum Naeem, Ivo Abraham
Publikováno v:
Journal of Medical Economics. 26:394-402
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0093feb5e6743ce716418a28a00ff4c
https://doi.org/10.1080/13696998.2023.2183680
https://doi.org/10.1080/13696998.2023.2183680
Autor:
Meteb Al‑Foheidi, Asem Albeshri, Safwan Moamenkahan, Abdulmajid Abdullah, Muhannad Abualola, Muath Alharbi, Ahmed Refa, Ali Bayer, Ahmed Shaheen, Syed Aga, Muhammad Khan, Mubarak Al‑Mansour, Ezzeldin Ibrahim
Publikováno v:
Molecular and clinical oncology. 17(1)
The addition of palbociclib (a cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) among patients with hormone receptor-positive (HR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed0d1d435f1071aaaca12031ed1c2d33
https://pubmed.ncbi.nlm.nih.gov/35747598
https://pubmed.ncbi.nlm.nih.gov/35747598
Autor:
J. Ayari, Hassan Errihani, Ahmed Saadeddine, Taha Filali, Khalid Alsaleh, Haleem Rasool, Hamouda Boussen, Meteb Al Foheidi, Farida Dabouz, Blaha Larbaoui, Adda Bounedjar, Hassen Mahfouf, Assia Bensalem, Marwan Ghosn, Mohammed Oukkal, Maria Arafah, K. Bouzid, Hikmat Abdel-Razeq, Alaa Kandil, Mohun Bahadoor, Nashwa Abdel-Aziz, Omalkhair Abulkhair, Jean-Marc Nabholtz, Heba Al Zahwahry, Sharif Kullab
Publikováno v:
JCO Global Oncology
PURPOSE Luminal, human epidermal growth factor receptor 2–negative breast cancer represents the most common subtype of breast malignancies. Neoadjuvant strategies of operable breast cancer are mostly based on chemotherapy, whereas it is not complet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e01af8abc0b805456849b1e2e65c82
https://pubmed.ncbi.nlm.nih.gov/34086481
https://pubmed.ncbi.nlm.nih.gov/34086481
Autor:
Meteb Al-Foheidi, Fatina M. Al Tahan, Ahmed Saadeddin, Hannah Chung, Banu Arun, Hany Abdel-Aziz, Mohamed Sabry, Manal Abdel-Wahab, Nivine Gado, Marwan Ghosn, Armando E. Giuliano, Azza Nasr, Hagar Elghazawy, Khaled Abdel Karim, Mona Frolova, Benjamin O. Anderson, Nermean Bahie Eldin, Heba M. El-Zawahry, Mohamed A Shehata, Lobna R. Ezz Elarab, Hussein Maki, Adel T. Aref, Rasha Kamal, Nivine Chalabi, Cheng Har Yip, Hesham Elghazaly, Jessica W.T. Leung, Charles M. Balch, Gilda Cardenosa
Publikováno v:
International journal of cancerREFERENCES. 149(3)
In low-middle income countries (LMICs) and the Middle East and North Africa (MENA) region, there is an unmet need to establish and improve breast cancer (BC) awareness, early diagnosis and risk reduction programs. During the 12th Breast, Gynecologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f5fa23b3c13ec75c35ffa7e10f1405c
https://pubmed.ncbi.nlm.nih.gov/33559295
https://pubmed.ncbi.nlm.nih.gov/33559295
Publikováno v:
Molecular and Clinical Oncology
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3 years following immunochemotherapy, 30-40% of patients will experience a relapse or a refra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9987372b9ffae89954c664af7cc57f5
https://doi.org/10.3892/mco.2020.2103
https://doi.org/10.3892/mco.2020.2103
Autor:
Ali M Alhomaidan, Tore Kristian Kvien, Mohammad A Alsenaidy, Aws Alshamsan, Musaed Alkholief, Ahmed Al-Jedai, Meteb Al-Foheidi, Gianluca Trifirò
Publikováno v:
Generics and Biosimilars Initiative Journal. 7:158-163
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::043fdab036432bbe1d46add3059f588e
https://doi.org/10.5639/gabij.2018.0704.032
https://doi.org/10.5639/gabij.2018.0704.032
Autor:
Mubarak Al-Mansour, Ruaa G Shafi, Hani Al Hashmi, Ahmed Alsaeed, Ezzeldin M. Ibrahim, Meteb Al-Foheidi, Solaf Kanfar
Publikováno v:
Oncology Research and Treatment. 40:288-292
Background: Hodgkin lymphoma (HL) exhibits considerable clinicopathological variations in different parts of the world. This study was prompted by the limited availability of HL data in developing countries (particularly long-term outcomes). Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40f4d8419852d0e542c22445c3be76ed
https://doi.org/10.1159/000460819
https://doi.org/10.1159/000460819
Autor:
Jean-Marc Nabholtz, Mohun Bahadoor, Mohammed Oukkal, Alaa Kandil, Marwan Ghosn, Hassan Errihani, K. Bouzid, Assia Bensalem, Blaha Larbaoui, Farida Dabouz, Nashwa A Abdulaziz, Heba Mohamed El Zawahry, Taha Fillali, Meteb Al-Foheidi, Hasen Mahfouf, Khalid Alsaleh, Adda Bounedjar, Sherif A Kullab
Publikováno v:
Journal of Clinical Oncology. 38:594-594
594 Background: While hormonal therapy (HT) is a fundamental treatment in breast cancer therapy, neoadjuvant NAHT is not considered standard. The SAFIA trial is a prospective international neoadjuvant Phase III investigating the potential role of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a6132b5be3be9b3d0bf9bf03bb6e5d4
https://doi.org/10.1200/jco.2020.38.15_suppl.594
https://doi.org/10.1200/jco.2020.38.15_suppl.594
Publikováno v:
Breast Cancer Research and Treatment. 152:463-476
The association between PIK3CA mutation and resistance to anti-HER2 therapy (AHT) is not precisely defined. This meta-analysis intended to explore the clinical utility of PIK3CA mutation in HER2-positive breast cancer treated with AHT. Literature sea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88bd886e184d00259baa044d806bf284
https://doi.org/10.1007/s10549-015-3480-6
https://doi.org/10.1007/s10549-015-3480-6